Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.

Park, Sun-Young et al.·Frontiers in nutrition·2025·Moderate EvidenceRandomized Controlled Trial
RPEP-12964Randomized Controlled TrialModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
N=80
Participants
Adults aged 40-75 with Kellgren-Lawrence grade I or II knee osteoarthritis

What This Study Found

Low-molecular-weight collagen peptides (3,000 mg/day) reduced knee osteoarthritis pain and improved physical function over 180 days compared to placebo in a double-blind trial of 80 patients.

Key Numbers

80 adults aged 40-75 with KL grade I-II OA. 3,000 mg/day LMCP vs placebo for 180 days. WOMAC pain change: -1.90 vs +0.61 (P = 0.006). WOMAC physical function and total scores also improved in the LMCP group.

How They Did This

Double-blind, randomized, placebo-controlled trial. 80 participants with KL grade I-II knee OA. Primary endpoint: WOMAC pain. Secondary: VAS, WOMAC function, joint space width, inflammatory markers. 180-day follow-up.

Why This Research Matters

Knee OA has few safe long-term treatments. This trial provides controlled evidence that collagen peptide supplements can reduce pain and improve function, offering a low-risk nutritional approach.

What This Study Doesn't Tell Us

Small sample size (80 participants). Only mild OA (KL grade I-II). 180-day duration may not capture long-term effects. Single study needs replication.

Trust & Context

Original Title:
Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
Published In:
Frontiers in nutrition, 12, 1644899 (2025)
Database ID:
RPEP-12964

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-12964·https://rethinkpeptides.com/research/RPEP-12964

APA

Park, Sun-Young; Lee, Sang-Hyun; Kim, Hyun Tae; Park, Hye-Jin; Kim, Do-Un; Kim, Seung Un; Heo, In. (2025). Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.. Frontiers in nutrition, 12, 1644899. https://doi.org/10.3389/fnut.2025.1644899

MLA

Park, Sun-Young, et al. "Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.." Frontiers in nutrition, 2025. https://doi.org/10.3389/fnut.2025.1644899

RethinkPeptides

RethinkPeptides Research Database. "Efficacy and safety of low-molecular-weight collagen peptide..." RPEP-12964. Retrieved from https://rethinkpeptides.com/research/park-2025-efficacy-and-safety-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.